Fibrosis inhibition and muscle histopathology improvement in laminin-α2-deficient mice

Muscle and Nerve

Volumn 42, Issue 2, 2010, Pages 218-229

  Nevo, Yoram ^a   Halevy, Orna ^b   Genin, Olga ^c   Moshe, Itai ^c   Turgeman, Tidhar ^b,c   Harel, Michal ^b,c   Biton, Edva ^a,d   Reif, Shimon ^d   Pines, Mark ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c VOLCANI CENTER   (Israel)

^d TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Collagen; Fibrosis; Halofuginone; Prolyl 4 hydroxylase; Smad3

Indexed keywords

HALOFUGINONE; LAMININ ALPHA2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; COLLAGEN SYNTHESIS; DRUG EFFICACY; FIBROBLAST; FIBROSIS; HINDLIMB; MOTOR COORDINATION; MOUSE; MUSCULAR DYSTROPHY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CELL COUNT; CELL PROLIFERATION; COLLAGEN; FIBROSIS; LAMININ; MICE; MICE, KNOCKOUT; MUSCLE STRENGTH; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, ANIMAL; PIPERIDINES; QUINAZOLINONES; ROTAROD PERFORMANCE TEST;

EID: 77955151335     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.21706     Document Type: Article

References (59)

1. Lisi MT, Cohn RD. Congenital muscular dystrophies: new aspects of an expanding group of disorders. Biochim Biophys Acta 2007;1772: 159-172.
2. Schessl J, Zou Y, Bönnemann CG. Congenital muscular dystrophies and the extracellular matrix. Semin Pediatr Neurol 2006;13:80-89. (Pubitemid 44486822)
3. Talim B, Kale G, Topaloglu H, Akçören Z, Caglar M, Gögüş S, et al. Clinical and histopathological study of merosin-deficient and merosin- positive congenital muscular dystrophy. Pediatr Dev Pathol 2000; 3:168-176. (Pubitemid 30112461)
4. Guglieri M, Magri F, Comi GP. Molecular etiopathogenesis of limb girdle muscular and congenital muscular dystrophies: boundaries and contiguities. Clin Chim Acta 2005;361:54-79. (Pubitemid 41382609)
5. Jimenez-Mallebrera C, Brown SC, Sewry CA, Muntoni F. Congenital muscular dystrophy: molecular and cellular aspects. Cell Mol Life Sci 2005;62:809-823. (Pubitemid 40655631)
6. Dunace VC, Stephens HR, Dunn M, Bailey AJ, Dubowitz V. A role for collagen in the pathogenesis of muscular dystrophy? Nature 1980;284:470-472.
7. Gosselin LE, Martinez DA. Impact of TNF-alpha blockade on TGF-beta1 and type I collagen mRNA expression in dystrophic muscle. Muscle Nerve 2004;30:244-246.
8. Hantai D, Labat-Robert J, Grimaud JA, Fardeau M. Fibronectin, laminin, type I, III and IV collagens in Duchenne's muscular dystrophy, congenital muscular dystrophies and congenital myopathies: an immunocytochemical study. Connect Tissue Res 1985;13: 273-281.
9. Stephens HR, Duance VC, Dunn MJ, Bailey AJ, Dubowitz V. Collagen types in neuromuscular diseases. J Neurol Sci 1982;53:45-62.
10. Vidal B, Serrano AL, Tjwa M, Suelves M, Ardite E, De Mori R, et al. Fibrinogen drives dystrophic muscle fibrosis via a TGFbeta/alternative macrophage activation pathway. Genes Dev 2008;22:1747-1752. (Pubitemid 351915499)
11. Zhao Y, Haginoya K, Sun G, Dai H, Onuma A, Iinuma K. Plateletderived growth factor and its receptors are related to the progression of human muscular dystrophy: an immunohistochemical study. J Pathol 2003;201:149-159. (Pubitemid 37121214)
12. Qiao C, Li J, Zhu T, Draviam R, Watkins S, Ye X, et al. Amelioration of laminin-alpha2-deficient congenital muscular dystrophy by somatic gene transfer of miniagrin. Proc Natl Acad Sci U S A 2005;102: 11999-12004. (Pubitemid 41291118)
13. Taniguchi M, Kurahashi H, Noguchi S, Sese J, Okinaga T, Tsukahara T, et al. Expression profiling of muscles from Fukuyama-type congenital muscular dystrophy and laminin-alpha 2 deficient congenital muscular dystrophy; is congenital muscular dystrophy a primary fibrotic disease? Biochem Biophys Res Commun 2006;342: 489-502.
14. Bernasconi P, Torchiana E, Confalonieri P, Brugnoni R, Barresi R, Mora M, et al. Expression of transforming growth factor-beta 1 in dystrophic patient muscles correlates with fibrosis. Pathogenetic role of a fibrogenic cytokine. J Clin Invest 1995;96:1137-1144.
15. Bernasconi P, Di Blasi C, Mora M, Morandi L, Galbiati S, Confalonieri P, et al. Transforming growth factor-beta1 and fibrosis in congenital muscular dystrophies. Neuromuscul Disord 1999;9:28-33. (Pubitemid 29079470)
16. Ishitobi M, Haginoya K, Zhao Y, Ohnuma A, Minato J, Yanagisawa T, et al. Elevated plasma levels of transforming growth factor beta1 in patients with muscular dystrophy. Neuroreport 2000;11:4033-4035. (Pubitemid 32038799)
17. Murakami N, McLennan IS, Nonaka I, Koishi K, Baker C, Hammond-Tooke G. Transforming growth factor-beta2 is elevated in skeletal muscle disorders. Muscle Nerve 1999;22:889-898. (Pubitemid 29330037)
18. Iannaccone S, Quattrini A, Smirne S, Sessa M, de Rino F, Ferini-Strambi L, et al. Connective tissue proliferation and growth factors in animal models of Duchenne muscular dystrophy. J Neurol Sci 1995;128:36-44.
19. Vainzof M, Ayub-Guerrieri D, Onofre PC, Martins PC, Lopes VF, Zilberztajn D, et al. Animal models for genetic neuromuscular diseases. J Mol Neurosci 2008;34:241-248.
20. Vilquin JT, Vignier N, Tremblay JP, Engvall E, Schwartz K, Fiszman M. Identification of homozygous and heterozygous dy2J mice by PCR. Neuromuscul Disord 2000;10:59-62. (Pubitemid 30006866)
21. van Lunteren E, Moyer M, Leahy P. Gene expression profiling of diaphragm muscle in {alpha>2-laminin (merosin) deficient dy/dy dystrophic mice. Physiol Genomics 2005;25:85-95.
22. Pines M, Nagler A. Halofuginone - a novel anti-fibrotic therapy. Gen Pharmacol 1998;30:445-450.
23. Pines M, Vlodavsky I, Nagler A. Halofuginone: from veterinary use to human therapy. Drug Dev Res 2000;50:371-378.
24. Pines M, Snyder D, Yarkoni S, Nagler A. Halofuginone to treat fibrosis in chronic graft versus host disease and scleroderma. Biol Blood Marrow Transplant 2003;9:417-425. (Pubitemid 38351799)
25. Pines M. Targeting TGFβ signaling to inhibit fibroblast activation as a therapy for fibrosis and cancer: effect of halofuginone. Expert Opin Drug Dis 2008;3:1-10.
26. McGaha TL, Phelps RG, Spiera H, Bona C. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming- growth-factor-beta-mediated Smad3 activation in fibroblasts. J Invest Dermatol 2002;118:461-470. (Pubitemid 34227163)
27. Halevy O, Nagler A, Levi-Schaffer F, Genina O, Pines M. Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients: effect of halofuginone. Biochem Pharmacol 1996;52:1057-1063. (Pubitemid 26338264)
28. Levi-Schaffer F, Nagler A, Slavin S, Knopov V, Pines M. Inhibition of collagen synthesis and changes in skin morphology in murine graft-versus-host disease and tight skin mice: effect of halofuginone. J Invest Dermatol 1996;106:84-88. (Pubitemid 26053386)
29. Pines M, Domb A, Ohana M, Inbar J, Genina O, Aleviev R, et al. Reduction in dermal fibrosis in the tight-skin (Tsk) mouse after local application of halofuginone. Biochem Pharmacol 2001;62:1221-1227. (Pubitemid 33055626)
30. Nagler A, Genina O, Lavelin I, Ohana M, Pines M. Halofuginone - an inhibitor of collagen type I synthesis - prevents formation of post-operative adhesions formation in the rat uterine horn model. Am J Obstet Gyn 1999;180:558-563. (Pubitemid 29149127)
31. Nagler A, Pines M. Topical treatment of cutaneous chronic graft versus host disease (cGvHD) with halofuginone: a novel inhibitor of collagen type I synthesis. Transplantation 1999;68:1806-1809. (Pubitemid 30004815)
32. Nagler A, Gofrit O, Ohana M, Pode D, Genina O, Pines M. The effect of halofuginone, an inhibitor of collagen type I synthesis, on urethral stricture formation in vivo and in vitro study in a rat model. J Urol 2000;164:1776-1780.
33. Bruck R, Genina O, Aeed H, Alexiev R, Nagler A, Pines M. Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats. Hepatology 2001;33:379-386. (Pubitemid 32119026)
34. Gnainsky Y, Kushnirsky Z, Bilu G, Hagai Y, Genina O, Volpin H, et al. Gene expression during chemically induced liver fibrosis: effect of halofuginone on TGF-beta signaling. Cell Tissue Res 2007;328: 153-166. (Pubitemid 46411910)
35. Zion O, Genin O, Kawada N, Yoshizato K, Roffe S, Nagler A, et al. Inhibition of the TGFb signaling by halofuginone as a modality for pancreas fibrosis prevention. Pancreas 2009;38:427-435.
36. Sundrud MS, Koralov SB, Feuerer M, Calado DP, Kozhaya AE, Rhule-Smith A, et al. Halofuginone inhibits TH17 cell differentiation by activating the amino acid starvation response. Science 2009;324: 1334-1338.
37. Ishii H, Choudhuri R, Mathias A, Sowers AL, Flanders KC, Cook JA, et al. Halofuginone mediated protection against radiation-induced leg contracture. Int J Oncol 2009;35:315-319.
38. Sheffer Y, Leon O, Pinthus JH, Nagler A, Mor Y, Genin O, et al. Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapy-mediated anti-tumoral effect. Mol Cancer Ther 2007;6:570-577. (Pubitemid 46332459)
39. Huebner KD, Jassal DS, Halevy O, Pines M, Anderson JE. Functional resolution of fibrosis in mdx mouse dystrophic heart and skeletal muscle by halofuginone. Am J Physiol Heart Circ Physiol 2008;294: H1550-H1561.
40. Turgeman T, Hagai Y, Huebner K, Jassal DS, Anderson J, Genin O, et al. Inhibition of Smad3 phosphorylation by halofuginone prevents muscle fibrosis and improves muscle performance in the mdx mouse model of Duchenne muscular dystrophy. Neuromuscul Disord 2008; 18:857-868.
41. Stupka N, Schertzer JD, Bassel-Duby R, Olson EN, Lynch GS. Stimulation of calcineurin Aα activity attenuates muscle pathophysiology in mdx dystrophic mice. Am J Physiol Regul Integ Comp Physiol 2008;294:R983-R992. (Pubitemid 351346977)
42. Halevy O, Piestun Y, Allouh MZ, Rosser BW, Rinkevich Y, Reshef R, et al. Pattern of Pax7 expression during myogenesis in the posthatch chicken establishes a model for satellite cell differentiation and renewal. Dev Dyn 2004;231:489-502. (Pubitemid 39410883)
43. Serradj N, Jamon M. Age-related changes in the motricity of the inbred mice strains 129/sv and C57BL/6j. Behav Brain Res 2006;177:80-89. (Pubitemid 46075155)
44. Tanase K, Teng Q, Krishnaney AA, Liu JK, Garrity-Moses ME, Boulis NM. Cervical spinal cord delivery of a rabies G protein pseudotyped lentiviral vector in the SOD-1 transgenic mouse. Invited submission from the Joint Section Meeting on Disorders of the Spine and Peripheral Nerves, March 2004. J Neurosurg Spine 2004;1:128-136.
45. Jannapureddy SR, Patel ND, Hwang W, Boriek AM. Genetic models in applied physiology - selected contribution: merosin deficiency leads to alterations in passive and active skeletal muscle mechanics. J Appl Physiol 2003;94:2524-2533.
46. Sun G, Haginoya K, Wu Y, Chiba Y, Nakanishi T, Onuma A, et al. Connective tissue growth factor is overexpressed in muscles of human muscular dystrophy. J Neurol Sci 2008;267:48-56. (Pubitemid 351248904)
47. Seale P, Sabourin LA, Girgis-Gabardo A, Mansouri A, Gruss P, Rudnicki MA. Pax7 is required for the specification of myogenic satellite cells. Cell 2000;102:777-786.
48. Zammit PS, Golding JP, Nagata Y, Hudon V, Partridge TA, Beauchamp JR. Muscle satellite cells adopt divergent fates: a mechanism for self-renewal? J Cell Biol 2004;166:347-357.
49. Vincent KJ, Jones E, Arthur MJ, Smart DE, Trim J, Wright MC, et al. Regulation of E-box DNA binding during in vivo and in vitro activation of rat and human hepatic stellate cells. Gut 2001;49:713-719. (Pubitemid 32989211)
50. Walker GA, Guerrero IA, Leinwand LA. Myofibroblasts: molecular crossdressers. Curr Top Dev Biol 2001;51:91-107.
51. Cohn RD, van Erp C, Habashi JP, Soleimani AA, Klein EC, Lisi MT, et al. Angiotensin II type 1 receptor blockade attenuates TGF-betainduced failure of muscle regeneration in multiple myopathic states. Nat Med 2007;13:204-210. (Pubitemid 46245764)
52. Melone MA, Peluso G, Petillo O, Galderisi U, Cotrufo R. Defective growth in vitro of Duchenne muscular dystrophy myoblasts: the molecular and biochemical basis. J Cell Biochem 1999;76:118-132. (Pubitemid 30010764)
53. Zanotti S, Saredi S, Ruggieri A, Fabbri M, Blasevich F, Romaggi S, et al. Altered extracellular matrix transcript expression and protein modulation in primary Duchenne muscular dystrophy myotubes. Matrix Biol 2007;26:615-624. (Pubitemid 350180391)
54. Fidzianska A, Goebel HH, Lenard HG, Heckmann C. Congenital muscular dystrophy (CMD) - a collagen formative disease? J Neurol Sci 1982;55:79-90.
55. Mezzano V, Cabrera D, Vial C, Brandan E. Constitutively activated dystrophic muscle fibroblasts show a paradoxical response to TGF-beta and CTGF/CCN2. J Cell Commun Signal 2007;1:205-217.
56. Alexakis C, Partridge T, Bou-Gharios G. Implication of the satellite cell in dystrophic muscle fibrosis: a self-perpetuating mechanism of collagen overproduction. Am J Physiol Cell Physiol 2007;293: C661-C669. (Pubitemid 47235183)
57. Roffe S, Hagai Y, Pines, Halevy O. Halofuginone inhibits smad3 phosphorylation via the P13K/Akt and MAPK/ERK pathways in muscle cells: Effect on myotube fusion. Exp Cell Res 2010;316: 1061-1069.
58. Spira G, Mawasi N, Paizi M, Anbinder N, Genina O, Alexiev R, et al. Halofuginone, a collagen type I inhibitor improves liver regeneration in cirrhotic rats. J Hepatol 2002;37:331-339. (Pubitemid 34969949)
59. de Jonge MJ, Dumez H, Verweij J, Yarkoni S, Snyder D, Lacombe D, et al. Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumors. Eur J Cancer 2006;42:1768-1774. (Pubitemid 44149080)